Pharming Group N.V.
PHARM.AS · AMS
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | €97,287 | €93,221 | €79,094 | €92,672 |
| % Growth | 4.4% | 17.9% | -14.7% | – |
| Cost of Goods Sold | €7,071 | €8,972 | €8,323 | €12,213 |
| Gross Profit | €90,216 | €84,249 | €70,771 | €80,459 |
| % Margin | 92.7% | 90.4% | 89.5% | 86.8% |
| R&D Expenses | €23,384 | €23,695 | €21,142 | €22,308 |
| G&A Expenses | €16,954 | €20,505 | €22,486 | €46,082 |
| SG&A Expenses | €51,081 | €51,554 | €57,056 | -€38,646 |
| Sales & Mktg Exp. | €34,127 | €31,049 | €34,570 | -€84,728 |
| Other Operating Expenses | -€72 | -€1,849 | -€383 | €90,093 |
| Operating Expenses | €74,393 | €73,400 | €77,815 | €73,755 |
| Operating Income | €15,823 | €10,849 | -€7,044 | €6,704 |
| % Margin | 16.3% | 11.6% | -8.9% | 7.2% |
| Other Income/Exp. Net | -€3,065 | -€3,770 | -€4,744 | -€26 |
| Pre-Tax Income | €12,758 | €7,079 | -€11,788 | €6,678 |
| Tax Expense | €5,209 | €2,529 | €3,100 | €3,819 |
| Net Income | €7,548 | €4,694 | -€14,719 | €2,859 |
| % Margin | 7.8% | 5% | -18.6% | 3.1% |
| EPS | 0.011 | 0.007 | -0.022 | 0.005 |
| % Growth | 61.4% | 131.8% | -558.3% | – |
| EPS Diluted | 0.011 | 0.007 | -0.022 | 0.005 |
| Weighted Avg Shares Out | 669,045 | 669,045 | 669,045 | 740,000 |
| Weighted Avg Shares Out Dil | 669,045 | 669,045 | 669,045 | 740,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | €485 | €659 | €604 | €2,197 |
| Interest Expense | €7,946 | €4 | €5,098 | €1,249 |
| Depreciation & Amortization | €2,726 | €2,702 | €2,582 | €7,699 |
| EBITDA | €23,430 | €9,785 | -€4,108 | €15,626 |
| % Margin | 24.1% | 10.5% | -5.2% | 16.9% |